Lupin Ltd Corporate Actions

Lupin gets USFDA approval for post-eye surgery drug

 Copy Link

This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.

Top Stocks for Today - 2nd July 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Godrej Properties, SBI Cards, Hyudai India, etc.

Lupin Expands US Presence with Launch of Prucalopride Tablets

 Copy Link

The tablets will be made at the company’s Goa facility, a site that has previously cleared global regulatory inspections and supports Lupin’s key exports.

Lupin Expands to China with Tiotropium Inhaler Deal Amid Rising COPD Cases

 Copy Link

The company said this deal fits into its larger strategy of expanding respiratory therapies beyond its home markets.

Lupin inks licensing pact with SteinCares for biosimilar

 Copy Link

StainCares added that partnership plans to enhance its biosimilar portfolio and back cost-effective healthcare in Latin America.

Top Stocks for Today - 27th May 2025

 Copy Link

Here are some of the stocks that may see significant price movement today: Lupin, IndiGo, Nazara Tech, Aurobindo Pharma, etc.

Lupin Secures USFDA Approval for Tolvaptan Tablets

 Copy Link

The drug will be manufactured at Lupin's facility in Nagpur, India, and the company has announced plans for a near-term launch in the U.S. market.

Lupin Gets USFDA Nod for Nagpur Injectable Plant After Clean Inspection

 Copy Link

The clearance is on the back of a four-day USFDA inspection between June 10 and June 13, 2024.

Lupin Acquires UK’s Renascience Pharma for ₹135 Crore

 Copy Link

The acquisition enhances Lupin’s portfolio of branded medicines and is aimed at furthering the company’s commitment to providing affordable and sustainable healthcare solutions.

Lupin Expands US Portfolio with USFDA Approval for Amifampridine

 Copy Link

Lupin said the tablets would be made at its Goa facility, which would bolster its global manufacturing capabilities and continued dedication to delivering affordable medications.